Central arteriovenous anastomosis in resistant hypertension?

The Lancet

Volumn 385, Issue 9978, 2015, Pages 1596-1597

  Schlaich, Markus ^a,b   Hering, Dagmara ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTERIOVENOUS FISTULA; ARTERY COMPLIANCE; CENTRAL ARTERIOVENOUS ANASTOMOSIS; DIASTOLIC BLOOD PRESSURE; DRUG THERAPY; FOLLOW UP; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERTENSION; NOTE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; VASCULAR RESISTANCE; ARTERIOVENOUS SHUNT; FEMALE; MALE; PROCEDURES;

ARTERIOVENOUS SHUNT, SURGICAL; FEMALE; HUMANS; HYPERTENSION; MALE;

EID: 84929511121     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62290-X     Document Type: Note

References (11)

1. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57: 1076-80.
2. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-19.
3. Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18: 1422-28.
4. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-42.
5. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol 2011; 58: 765-73.
6. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-09.
7. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-401.
8. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet 2012; 380: 591-600.
9. Lobo MD, Sobotka PA, Stanton A, et al, for the ROX CONTROL HTN Investigators. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet 2015; published online Jan 23. http://dx.doi.org/10.1016/S0140-6736(14)62053-5.
10. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31: 766-74.
11. Patel HC, Hayward C, Ozdemir BA, et al. Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation. Hypertension 2014; published online Nov 17. DOI:10.1161/HYPERTENSIONAHA.114.04640.